Quantitative JAK2 mutation testing can not only provide prognostic information about MPN and monitor minimal residual disease after stem cell transplant for JAK2-positive patients with myelofibrosis but also be used to monitor disease progression and response to therapy [10–12]. This evidence concerns the gene JAK2 and myeloproliferative disorder.